Pegaptanib sodium for the treatment of age-related macular degeneration

Keyphrases

• Age-related Macular Degeneration 100%
• Pegaptanib 100%
• Ocular Neovascular Disease 100%
• Pegaptanib Sodium 100%
• Clinical Trials 50%
• Pathologic 50%
• Clinical Efficacy 50%
• Safety Profile 50%
• Diabetic Retinopathy 50%
• Vascular Endothelial Growth Factor 50%
• Systematic Literature Review 50%
• Vascular Permeability 50%
• Clinical Safety 50%
• Pharmacology 50%
• Myopic Choroidal Neovascularization (mCNV) 50%
• Antiangiogenic Agents 50%
• Therapeutic Benefits 50%
• Systemic Safety 50%
• Retinal Vein Occlusion 50%
• Diabetic Retinal 50%
• Ocular Neovascularization 50%
• Ocular Safety 50%
• Aptamer Therapeutics 50%

Medicine and Dentistry

• Age Related Macular Degeneration 100%
• Pegaptanib 100%
• Diseases 50%
• Clinical Trial 25%
• Systematic Review 25%
• Vasculotropin 25%
• Angiogenesis Inhibitor 25%
• Diabetic Retinopathy 25%
• Choroidal Neovascularization 25%
• Blood Vessel Permeability 25%
• Aptamer 25%
• Retina Vein Occlusion 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Age Related Macular Degeneration 100%
• Pegaptanib 100%
• Diseases 50%
• Clinical Trial 25%
• Vasculotropin 25%
• Angiogenesis Inhibitor 25%
• Neovascularization (Pathology) 25%
• Clinical Pharmacology 25%
• Subretinal Neovascularization 25%
• Diabetic Retinopathy 25%
• Aptamer 25%
• Retina Vein Occlusion 25%